AxoGen (NASDAQ:AXGN) Director Kathy Johnson Weiler Sells 16,344 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Kathy Johnson Weiler sold 16,344 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $44.09, for a total transaction of $720,606.96. Following the completion of the transaction, the director owned 16,344 shares in the company, valued at $720,606.96. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

AxoGen Stock Down 3.1%

Shares of NASDAQ AXGN opened at $42.06 on Friday. The company has a market capitalization of $2.24 billion, a P/E ratio of -65.72 and a beta of 1.17. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $45.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. The company’s 50 day moving average price is $34.20 and its 200-day moving average price is $31.15.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%. Equities analysts forecast that AxoGen, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AXGN. Royal Bank of Canada lifted its position in shares of AxoGen by 14.2% during the 1st quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider’s stock valued at $704,000 after acquiring an additional 4,723 shares during the period. AQR Capital Management LLC lifted its position in shares of AxoGen by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider’s stock valued at $442,000 after acquiring an additional 7,453 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock valued at $466,000 after acquiring an additional 1,057 shares during the period. Jones Financial Companies Lllp lifted its position in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 10,481 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of AxoGen by 37.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider’s stock valued at $4,113,000 after acquiring an additional 103,072 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Lake Street Capital boosted their target price on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Raymond James Financial reiterated an “outperform” rating and set a $48.00 target price on shares of AxoGen in a research report on Wednesday, April 29th. Finally, Citigroup reiterated an “outperform” rating on shares of AxoGen in a research report on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.50.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.